Intra-Cellular Therapies CEO Sharon Mates' 2021 pay jumps 32% to $7.2M
Intra-Cellular Therapies reports 2021 executive compensation
By ExecPay News
Published: April 21, 2022
Intra-Cellular Therapies reported fiscal year 2021 executive compensation information on April 21, 2022.
In 2021, five executives at Intra-Cellular Therapies received on average a compensation package of $3.6M, a 23% increase compared to previous year.
Average pay of disclosed executives at Intra-Cellular Therapies
Sharon Mates, Chief Executive Officer, received $7.2M in total, which increased by 32% compared to 2020. 48% of Mates' compensation, or $3.5M, was in stock awards. Mates also received $1.4M in bonus, $1.5M in option awards, $794K in salary, as well as $24K in other compensation.
For fiscal year 2021, the median employee pay was $199,300 at Intra-Cellular Therapies. Therefore, the ratio of Sharon Mates' pay to the median employee pay was 36 to one.
Michael I. Halstead, General Counsel, received a compensation package of $2.8M, which increased by 15% compared to previous year. 43% of the compensation package, or $1.2M, was in stock awards.
Suresh Durgam, Chief Medical Officer, earned $2.8M in 2021, a 44% increase compared to previous year.
Mark Neumann, Executive Vice President, Chief Commercial Officer, received $2.8M in 2021, which increases by 7% compared to 2020.
Lawrence J. Hineline, Chief Financial Officer, earned $2.4M in 2021, a 11% increase compared to previous year.
Related executives
Sharon Mates
Intra-Cellular Therapies
Chief Executive Officer
Lawrence Hineline
Intra-Cellular Therapies
Chief Financial Officer
Suresh Durgam
Intra-Cellular Therapies
Chief Medical Officer
Michael Halstead
Intra-Cellular Therapies
General Counsel
Mark Neumann
Intra-Cellular Therapies
Executive Vice President, Chief Commercial Officer
You may also like
Source: SEC filing on April 21, 2022.